Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aflibercept/nesvacumab - Bayer/Regenron Pharmaceuticals

Next Previous
Search
Drug Profile

Aflibercept/nesvacumab - Bayer/Regenron Pharmaceuticals

Alternative Names: Aflibercept/Ang2-antibody; Ang2 antibody/Eylea; Ang2-antibody/aflibercept; Eylea/Ang2-antibody; Eylea/nesvacumab; Nesvacumab/aflibercept; Nesvacumab/Eylea; REGN 910-3; REGN-910/Eylea

Latest Information Update: 29 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Eye disorder therapies; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Angiopoietin-2 inhibitors; Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic macular oedema; Wet age-related macular degeneration

Most Recent Events

  • 29 Sep 2021 Discontinued - Phase-II for Diabetic macular oedema in USA (Intravitreous) (Regeneron Pharmaceuticals pipeline, September 2021)
  • 29 Sep 2021 Discontinued - Phase-II for Wet age-related macular degeneration (In the elderly, In adults) in USA (Intravitreous) (Regeneron Pharmaceuticals pipeline, September 2021)
  • 03 Oct 2017 Regeneron Pharmaceuticals completes the phase II ONYX trial in Wet age-related macular degeneration (In adults, In the elderly) in USA (Intravitreous) (NCT02713204)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top